Background and Objectives The clinical significance of immune thrombocytopenia ( ITP ) is mainly reflected by bleeding and/or bleeding risks, which, in some cases, cannot be adequately controlled by standard therapy. Tranexamic acid ( TA ) is increasingly used in preventing and reducing bleeding in several medical settings. There is little information on whether TA may also be useful in the management of ITP . Materials and Methods Twelve patients with ITP were treated with TA (0·5–3 g/day) due to recognizable bleeding. Ten of the 12 patients were under regular treatment for ITP . The remaining two patients did not require additional therapy. Results Cessation or, at least, significant improvement of bleeding was achieved shortly after the initiation of TA in all cases. TA was well tolerated and discontinued after cessation of bleeding. Conclusions We recommend the use of TA in ITP patients with bleeding and/or an increased bleeding risk. Ultimately, cessation of bleeding plays a key role in the management of such affected patients. However, future studies are required to optimize dose and administration routes (intravenous or oral).
展开▼
